Publication of standalone interim report (SA-P) for H1/ FY2025 (Q4 of the calendar year 2025 and Q1 of the calendar year 2026)
21.05.2026
See also
Synektik plans to devide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE
- Corporate news
- Investor relations
Extraordinary Shareholders’ Meeting on 19 May 2026
- Corporate news
- Investor relations
Synektik shareholders have unanimously approved the division of the company and spinoff of the cardiotracer project to Syn2bio
- Corporate news
- Investor relations